AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
quantisnow.com/i/ataibeckley-announces-positi...Posted Nov 10, 2025, 12:03 PM UTC
10